1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 3.4 Market Trends 4. Key Insights 4.1 Prevalence ofNeurodegenerative Diseases - For Key Countreis, 2018 4.2 Regulatory Scenario - For KeyCountries 4.3 Patent Snapshot 4.3 New Product Launch 4.4 Pipeline Analysis 4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships 5. GlobalNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insightsand Forecast – By Drug Class 5.2.1Immunomodulators 5.2.2Interferons 5.2.3Decarboxylase Inhibitors 5.2.4 DopamineAgonists 5.2.4 Others 5.3. Market Analysis, Insightsand Forecast – By Disease Indication 5.3.1 MultipleSclerosis 5.3.2Parkinson’s Disease 5.3.3Alzheimer's Disease 5.3.4 SpinalMuscular Atrophy (SMA) 5.3.5 Others 5.4. Market Analysis, Insightsand Forecast – By Route of Administration 5.4.1 Oral 5.4.2Injection 5.4.3Transdermal 5.5. Market Analysis, Insightsand Forecast – By Distribution Channel 5.5.1 HospitalPharmacy 5.5.2 RetailPharmacy 5.5.3 OnlinePharmacy 5.6. Market Analysis, Insightsand Forecast – By Region 5.6.1 NorthAmerica 5.6.2 Europe 5.6.3 Asia Pacific 5.6.4 LatinAmerica 5.6.5 MiddleEast & Africa 6. North AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By DrugClass 6.2.1Immunomodulators 6.2.2Interferons 6.2.3Decarboxylase Inhibitors 6.2.4 DopamineAgonists 6.2.4 Others 6.3. Market Analysis, Insightsand Forecast – By Disease Indication 6.3.1 MultipleSclerosis 6.3.2Parkinson’s Disease 6.3.3Alzheimer's Disease 6.3.4 SpinalMuscular Atrophy (SMA) 6.3.5 Others 6.3. Market Analysis – By Routeof Administration 6.4.1 Oral 6.4.2Injection 6.4.3Transdermal 6.4. Market Analysis – ByDistribution Channel 6.5.1 HospitalPharmacy 6.5.2 RetailPharmacy 6.5.3 Online Pharmacy 6.5. Market Analysis – By Country 6.6.1 U.S. 6.6.2 Canada 7. EuropeNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By DrugClass 7.2.1Immunomodulators 7.2.2Interferons 7.2.3Decarboxylase Inhibitors 7.2.4 DopamineAgonists 7.2.4 Others 7.3. Market Analysis, Insightsand Forecast – By Disease Indication 7.3.1 MultipleSclerosis 7.3.2Parkinson’s Disease 7.3.3Alzheimer's Disease 7.3.4 SpinalMuscular Atrophy (SMA) 7.3.5 Others 7.4. Market Analysis – By Routeof Administration 7.4.1 Oral 7.4.2Injection 7.4.3Transdermal 7.5. Market Analysis – ByDistribution Channel 7.5.1 Hospital Pharmacy 7.5.2 RetailPharmacy 7.5.3 OnlinePharmacy 7.6. Market Analysis – ByCountries/ Sub regions 7.6.1 U.K. 7.6.2 Germany 7.6.3 France 7.6.4 Italy 7.6.5 Spain 7.6.6Scandinavia 7.6.7 Rest ofEurope 8. Asia PacificNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By DrugClass 8.2.1Immunomodulators 8.2.2Interferons 8.2.3Decarboxylase Inhibitors 8.2.4 DopamineAgonists 8.2.4 Others 8.3. Market Analysis, Insightsand Forecast – By Disease Indication 8.3.1 MultipleSclerosis 8.3.2Parkinson’s Disease 8.3.3Alzheimer's Disease 8.3.4 SpinalMuscular Atrophy (SMA) 8.3.5 Others 8.4. Market Analysis – By Routeof Administration 8.4.1 Oral 8.4.2Injection 8.4.3 Transdermal 8.5. Market Analysis – ByDistribution Channel 8.5.1 Hospital Pharmacy 8.5.2 RetailPharmacy 8.5.3 OnlinePharmacy 8.6. Market Analysis – ByCountries/ Sub regions 8.6.1 Japan 8.6.2 China 8.6.3 India 8.6.4Australia 8.6.5Southeast Asia 8.6.6 Rest ofAsia Pacific 9. Latin AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By DrugClass 9.2.1Immunomodulators 9.2.2Interferons 9.2.3Decarboxylase Inhibitors 9.2.4 DopamineAgonists 9.2.4 Others 9.3. Market Analysis, Insightsand Forecast – By Disease Indication 9.3.1 MultipleSclerosis 9.3.2Parkinson’s Disease 9.3.3Alzheimer's Disease 9.3.4 SpinalMuscular Atrophy (SMA) 9.3.5 Others 9.4. Market Analysis – By Routeof Administration 9.4.1 Oral 9.4.2Injection 9.4.3Transdermal 9.5. Market Analysis – ByDistribution Channel 9.5.1 HospitalPharmacy 9.5.2 RetailPharmacy 9.5.3 OnlinePharmacy 9.6. Market Analysis – ByCountries/ Sub regions 9.6.1 Brazil 9.6.2 Mexico 9.6.3 Rest ofLatin America 10. Middle East &Africa Neurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By DrugClass 10.2.1Immunomodulators 10.2.2 Interferons 10.2.3Decarboxylase Inhibitors 10.2.4Dopamine Agonists 10.2.4 Others 10.3. Market Analysis, Insightsand Forecast – By Disease Indication 10.3.1Multiple Sclerosis 10.3.2Parkinson’s Disease 10.3.3Alzheimer's Disease 10.3.4 SpinalMuscular Atrophy (SMA) 10.3.5 Others 10.4. Market Analysis – By Routeof Administration 10.4.1 Oral 10.4.2Injection 10.4.3Transdermal 10.5. Market Analysis – ByDistribution Channel 10.5.1Hospitals 10.5.2 RetailPharmacy 10.5.3 OnlinePharmacy 10.6. Market Analysis – ByCountries/ Sub regions 10.6.1 SouthAfrica 10.6.2 GCC 10.6.3 Rest ofMiddle East & Africa 11. CompetitiveAnalysis 11.1. Key Industry Developments 11.2. Global Market ShareAnalysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis –Major Players 11.5. Company Profiles (Overview,Drug Classs & services, SWOT analysis, Recent developments, strategies,financials (based on availability)) 11.5.1 Biogen 11.5.2 Pfizer,Inc. 11.5.3 F.Hoffmann-La Roche Ltd 11.5.4 Merck& Co., Inc. 11.5.5Novartis AG 11.5.6 Sanofi 11.5.7 TevaPharmaceutical Industries Ltd. 11.5.8 OrionPharma 11.5.9 UCB S.A 11.5.10 ACADIAPharmaceuticals Inc. 11.5.11 H.Lundbeck A/S 11.5.12Mitsubishi Tanabe Pharma Corporation 11.5.13 OtherProminent Players 12. StrategicRecommendation

Biogen Pfizer, Inc. Hoffmann-La Roche Ltd Merck & Co., Inc. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd. Orion Pharma UCB S.A ACADIA Pharmaceuticals Inc. Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Other players